These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 8627865)

  • 1. RE: Prostate specific antigen after gonadal androgen withdrawal and deferred flutamide treatment.
    Walsh PC
    J Urol; 1996 May; 155(5):1705. PubMed ID: 8627865
    [No Abstract]   [Full Text] [Related]  

  • 2. RE: Prostate specific antigen after gonadal androgen withdrawal and deferred flutamide treatment.
    Small EJ
    J Urol; 1996 May; 155(5):1704-5. PubMed ID: 8627864
    [No Abstract]   [Full Text] [Related]  

  • 3. Re: Characterization of patients with androgen independent prostatic carcinoma whose serum prostate specific antigen decreased following flutamide withdrawal.
    Small EJ
    J Urol; 1997 Aug; 158(2):552. PubMed ID: 9224356
    [No Abstract]   [Full Text] [Related]  

  • 4. Prostate specific antigen after gonadal androgen withdrawal and deferred flutamide treatment.
    Fowler JE; Pandey P; Seaver LE; Feliz TP
    J Urol; 1995 Aug; 154(2 Pt 1):448-53. PubMed ID: 7541862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adrenal androgen levels as predictors of outcome in castration-resistant prostate cancer patients treated with combined androgen blockade using flutamide as a second-line anti-androgen.
    Narimoto K; Mizokami A; Izumi K; Mihara S; Sawada K; Sugata T; Shimamura M; Miyazaki K; Nishino A; Namiki M
    Int J Urol; 2010 Apr; 17(4):337-45. PubMed ID: 20202011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer.
    Small EJ; Srinivas S
    Cancer; 1995 Oct; 76(8):1428-34. PubMed ID: 8620419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic options in patients with hormone-refractory prostate cancer.
    Anand N
    Am J Med; 1996 Feb; 100(2):243-4. PubMed ID: 8629663
    [No Abstract]   [Full Text] [Related]  

  • 8. Prostate specific antigen in black and white men after hormonal therapies for prostate cancer.
    Fowler JE; Bigler SA; Renfroe DL; Dabagia MD
    J Urol; 1997 Jul; 158(1):150-4. PubMed ID: 9186343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
    Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
    J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of flutamide as a second-line agent for maximum androgen blockade of hormone refractory prostate cancer.
    Nishimura K; Arichi N; Tokugawa S; Yoshioka I; Kishikawa H; Ichikawa Y
    Int J Urol; 2007 Mar; 14(3):264-7. PubMed ID: 17430272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Neoadjuvant hormone therapy with total radical prostatectomy: intermediate results].
    Hermans BP; Lorge F; Wese FX; Opsomer RJ; Van Cangh PJ
    Acta Urol Belg; 1996 Mar; 64(1):27-31. PubMed ID: 8659332
    [No Abstract]   [Full Text] [Related]  

  • 12. Response of carcinoma of the prostate to withdrawal of flutamide.
    Collinson MP; Daniel F; Tyrrell CJ; Teasdale C
    Br J Urol; 1993 Nov; 72(5 Pt 1):662-3. PubMed ID: 10071562
    [No Abstract]   [Full Text] [Related]  

  • 13. Neoadjuvant hormone therapy and radical radiotherapy for localized prostate cancer: poorer biochemical outcome using flutamide alone.
    Wilson KS; Ludgate CM; Wilson AG; Alexander AS
    Can J Urol; 2000 Oct; 7(5):1099-103. PubMed ID: 11114872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II study of nilutamide in men with prostate cancer after the failure of flutamide or bicalutamide therapy.
    Davis NB; Ryan CW; Stadler WM; Vogelzang NJ
    BJU Int; 2005 Oct; 96(6):787-90. PubMed ID: 16153201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma.
    Boccon-Gibod L; Fournier G; Bottet P; Marechal JM; Guiter J; Rischman P; Hubert J; Soret JY; Mangin P; Mallo C; Fraysse CE
    Eur Urol; 1997; 32(4):391-5; discussion 395-6. PubMed ID: 9412794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-acting gonadotropin-releasing hormone implant to maintain medical castration for two years in men with prostate cancer.
    Spitz IM; Chertin B; Lindenberg T; Farkas A
    N Engl J Med; 1999 May; 340(18):1439. PubMed ID: 10328706
    [No Abstract]   [Full Text] [Related]  

  • 17. Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade.
    Schellhammer PF; Venner P; Haas GP; Small EJ; Nieh PT; Seabaugh DR; Patterson AL; Klein E; Wajsman Z; Furr B; Chen Y; Kolvenbag GJ
    J Urol; 1997 May; 157(5):1731-5. PubMed ID: 9112515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer.
    Miyake H; Hara I; Eto H
    BJU Int; 2005 Oct; 96(6):791-5. PubMed ID: 16153202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bicalutamide for advanced prostate cancer: the natural versus treated history of disease.
    Scher HI; Liebertz C; Kelly WK; Mazumdar M; Brett C; Schwartz L; Kolvenbag G; Shapiro L; Schwartz M
    J Clin Oncol; 1997 Aug; 15(8):2928-38. PubMed ID: 9256137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy.
    Joyce R; Fenton MA; Rode P; Constantine M; Gaynes L; Kolvenbag G; DeWolf W; Balk S; Taplin ME; Bubley GJ
    J Urol; 1998 Jan; 159(1):149-53. PubMed ID: 9400459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.